factor IX gene therapy etranacogene dezaparvovec
Selected indexed studies
- Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B. (N Engl J Med, 2023) [PMID:36812434]
- Etranacogene dezaparvovec-drlb gene therapy for patients with hemophilia B (congenital factor IX deficiency). (Expert Opin Biol Ther, 2023) [PMID:37962325]
- Gene therapy for hemophilia. (Hematology Am Soc Hematol Educ Program, 2022) [PMID:36485127]
_Worker-drafted node — pending editorial review._
Connections
factor IX gene therapy etranacogene dezaparvovec is a side effect of
Sources
- Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B. (2023) pubmed
- Etranacogene dezaparvovec-drlb gene therapy for patients with hemophilia B (congenital factor IX deficiency). (2023) pubmed
- Gene therapy for hemophilia. (2022) pubmed
- Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial. (2024) pubmed
- Completion of phase 2b trial of etranacogene dezaparvovec gene therapy in patients with hemophilia B over 5 years. (2025) pubmed
- Etranacogene dezaparvovec for hemophilia B gene therapy. (2021) pubmed
- Hemophilia B and gene therapy: a new chapter with etranacogene dezaparvovec. (2024) pubmed
- Etranacogene Dezaparvovec: First Approval. (2023) pubmed
- Evaluation of One-Stage Assays for the Monitoring of Recombinant Human Factor IX Padua Activity After Etranacogene Dezaparvovec Gene Therapy. (2025) pubmed
- Comprehensive analysis and prediction of long-term durability of factor IX activity following etranacogene dezaparvovec gene therapy in the treatment of hemophilia B. (2023) pubmed